EUVIMEDEUVIMED entdecken
Crossref

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Advanced Ovarian Carcinoma: Initial Experience in Mexico

Horacio Noé López-Basave, Flavia Morales-Vásquez, Juan M. Medina-Castro, Isaías Padilla-Mota, Juan M. Ruiz-Molina

Advances in Surgical Sciences · 20.08.2013 · 1 (2) · 6-10

DOI: 10.11648/j.ass.20130102.11 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Surgical Sciences, online erschienen am 20.08.2013. Verfasst von Horacio Noé López-Basave und 4 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ovarian cancer is a lethal tumor, 70% of which occurs in locally advanced stages. Despite its high initial response rate to chemotherapy, recurrence takes place in up to 90%. Prognosis of recurrent disease remains poor. In recent years, a new approach has been developed, combining a maximal cytoreductive effort with Hyperthermic intraperitoneal chemotherapy (HIPEC).

Methods

We conducted a pilot study of 14 patients with recurrent ovarian cancer who were treated with Cytoreductive surgery (CRS) and HIPEC at the Mexico City-based National Cancer Institute of México (INCan) between January 2007 and January 2012.

Results

There were 14 patients with recurrent ovarian cancer, including 13 with clinical stage IIIC and one with clinical stage CEIV due to retroperitoneal tumor with recurrence. Average age was 52 years (range, 20–72 years). Mortality and morbidity rates were 0 and 40%, respectively. Average surgical operative time was 7.5 h (range, 4.7–11 h). Average bleeding amounted to 1,171 mL (range, 100–3,700 mL).Overall median survival (OMS) was 14 months (range, 2–37 months). Peritoneal carcinomatosis index (PCI) showed eight patients with 20 points. Bleeding correlates with the PCI of >20 points. Performance status was a significant prognostic factor in patients with extensive peritoneal carcinomatosis (PCI, >20).

Conclusions

Therapy combining CRS and HIPEC is feasible in selected patients with recurrent ovarian carcinoma with high morbidity. With ovarian cancer, novel therapies should be explored, one of which could be HIPEC.

Zitieren

APA

López-Basave, H. N., Morales-Vásquez, F., Medina-Castro, J. M., Padilla-Mota, I., & Ruiz-Molina, J. M. (2013). Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Advanced Ovarian Carcinoma: Initial Experience in Mexico. Advances in Surgical Sciences, 1(2), 6-10. https://doi.org/10.11648/j.ass.20130102.11

Vancouver

López-Basave HN, Morales-Vásquez F, Medina-Castro JM, Padilla-Mota I, Ruiz-Molina JM. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Advanced Ovarian Carcinoma: Initial Experience in Mexico. Advances in Surgical Sciences. 2013;1(2):6-10. doi:10.11648/j.ass.20130102.11

BibTeX
@article{LpezBasave2013,
  author = {López-Basave, Horacio Noé and Morales-Vásquez, Flavia and Medina-Castro, Juan M. and Padilla-Mota, Isaías and Ruiz-Molina, Juan M.},
  title = {Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Advanced Ovarian Carcinoma: Initial Experience in Mexico},
  journal = {Advances in Surgical Sciences},
  year = {2013},
  volume = {1},
  number = {2},
  pages = {6--10},
  doi = {10.11648/j.ass.20130102.11}
}
Kostenlos starten →